Skip to content
Search

Latest Stories

Britons warned of hospital crisis over Omicron surge but vaccine minister says patients are showing less severe symptoms

Britain on Tuesday (January 4) faced warnings of an impending hospital crisis due to staff shortages caused by a wave of Omicron infections, as the country returned to work after Christmas.

However, Britain's vaccine minister said hospitalized Covid-19 patients were showing less severe symptoms than before, adding that there was no need for further restrictions at this stage.


Prime minister Boris Johnson resisted imposing stringent lockdown measures in England ahead of New Year as Omicron fueled a spike in cases to record highs.

While hospitalizations are rising they have not tracked the trajectory of daily cases, possibly reflecting the impact of vaccines and booster shots, the likely lower severity of Omicron and the time lag in people going into hospital.

"At the moment, if you look at the people who have been hospitalized, they are going in with less severe conditions than before," minister for Vaccines and Public Health Maggie Throup told Sky News, adding that the "Plan B" Johnson brought in in December was working.

"The numbers that are in hospital beds is about half what it was a year ago - and that just shows the power of the vaccine."

Neil Ferguson, an epidemiologist at Imperial College London, said that while infections in London in under-50s may have plateaued, the incredibly steep spike in that age group had not yet had time to spread to older age groups, which are more vulnerable to Covid-19.

"We may see a different pattern in hospitalizations. Hospitalizations are still generally going up across the country, and we may see high levels for some weeks," he told BBC Radio.

"Vaccination is holding up in terms of protection against severe disease, assisted by the fact that Omicron almost certainly is substantially less severe, but it still puts pressures on the health system."

Almost impossible

Matthew Taylor, chief executive of the NHS Confederation which represents healthcare providers in England, Wales and Northern Ireland, said cases appeared to have levelled off in London.

But he told Times Radio that staff shortages and rising cases across the rest of the country were a concern.

"The unpredictability of staff absence means NHS leaders having to work around the clock just thinking about how they can deploy their resources best to deal with the most urgent and pressing needs," he added.

"Even using all their imagination and creativity, it is becoming almost impossible, which is why we see hospitals declaring critical incidents."

Anyone testing positive for the virus has to self-isolate for 10 days, or seven days if they produce a negative test.

There have been calls to ease those restrictions for health staff to ease what Johnson on Monday said was "considerable pressure" on hospitals.

Taylor said reducing the self-isolation period to five days should only be done if the data indicated it was "absolutely safe".

Pupils returning to school also faced the prospect of mass staff absences and merged classes.

Secondary school pupils have been advised to wear face masks in class as a "temporary" measure.

Transport networks also battled absences, leaving commuters facing long waits on their return to work, while other public services such as household bin collections were hampered.

Britain has seen nearly 149,000 deaths since the start of the pandemic in early 2020 and Johnson has defended his decision not to increase restrictions over Christmas in England, unlike in other parts of the UK.

A review of restrictions is expected this week.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less